US 11,866,770 B2
Spatially encoded biological assays
Mark S. Chee, San Diego, CA (US)
Assigned to Prognosys Biosciences, Inc., San Diego, CA (US)
Filed by Prognosys Biosciences, Inc., San Diego, CA (US)
Filed on May 26, 2023, as Appl. No. 18/324,727.
Application 18/324,727 is a continuation of application No. 17/969,160, filed on Oct. 19, 2022, granted, now 11,732,292.
Application 17/969,160 is a continuation of application No. 17/692,830, filed on Mar. 11, 2022, granted, now 11,542,543, issued on Jan. 3, 2023.
Application 17/692,830 is a continuation of application No. 16/894,369, filed on Jun. 5, 2020, granted, now 11,293,917, issued on Apr. 5, 2022.
Application 16/894,369 is a continuation of application No. 16/435,176, filed on Jun. 7, 2019, abandoned.
Application 16/435,176 is a continuation of application No. 16/430,015, filed on Jun. 3, 2019, abandoned.
Application 16/430,015 is a continuation of application No. 16/414,213, filed on May 16, 2019, granted, now 10,787,701, issued on Sep. 29, 2020.
Application 16/414,213 is a continuation of application No. 16/402,098, filed on May 2, 2019, granted, now 10,472,669, issued on Nov. 12, 2019.
Application 16/402,098 is a continuation of application No. 16/276,235, filed on Feb. 14, 2019, granted, now 10,480,022, issued on Nov. 19, 2019.
Application 16/276,235 is a continuation of application No. 15/187,661, filed on Jun. 20, 2016, granted, now 10,308,982, issued on Jun. 4, 2019.
Application 15/187,661 is a continuation of application No. 13/080,616, filed on Apr. 5, 2011, granted, now 9,371,598, issued on Jun. 21, 2016.
Claims priority of provisional application 61/321,124, filed on Apr. 5, 2010.
Prior Publication US 2023/0323436 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6837 (2018.01); G01N 33/68 (2006.01); C12Q 1/6804 (2018.01); C12Q 1/6874 (2018.01); G01N 33/53 (2006.01); C12Q 1/6869 (2018.01); C40B 60/04 (2006.01); C12Q 1/6809 (2018.01); C12Q 1/6834 (2018.01); C12Q 1/6841 (2018.01); C40B 30/04 (2006.01); G01N 33/543 (2006.01); C12Q 1/68 (2018.01); B01L 3/00 (2006.01); C12Q 1/6876 (2018.01); C12Q 1/6858 (2018.01)
CPC C12Q 1/6837 (2013.01) [B01L 3/502715 (2013.01); C12Q 1/68 (2013.01); C12Q 1/6804 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6834 (2013.01); C12Q 1/6841 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6874 (2013.01); C12Q 1/6876 (2013.01); C40B 30/04 (2013.01); C40B 60/04 (2013.01); G01N 33/5308 (2013.01); G01N 33/543 (2013.01); G01N 33/54366 (2013.01); G01N 33/6845 (2013.01); C12Q 1/6858 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2458/10 (2013.01)] 24 Claims
 
1. A system comprising:
a microcircuit arrangement and software configured to cause the microcircuit arrangement to associate a target nucleic acid on a substrate to a location in a tissue section; and
a plurality of probes contacted with the tissue section, wherein a probe of the plurality of probes comprises a capture agent, and wherein the capture agent comprises:
(i) a binding sequence configured to bind the target nucleic acid, or a portion thereof, of the tissue section, and
(ii) a coding tag sequence that corresponds to a location of the target nucleic acid in the tissue section,
wherein the software is further configured to cause the microcircuit arrangement to:
correlate the coding tag sequence, or a complement thereof, from its location on the substrate to its location in the tissue section; and
associate the coding tag sequence, or the complement thereof, to the target nucleic acid, or a complement thereof, configured to bind the binding sequence, thereby associating the target nucleic acid on the substrate to its location in the tissue section.